Dacomitinib, an Irreversible Pan-ErbB Inhibitor Significantly Abrogates Growth in Head and Neck Cancer Models That Exhibit Low Response to Cetuximab

類似資料

• Pre-clinical characterization of Dacomitinib (PF-00299804), an irreversible pan-ErbB inhibitor, combined with ionizing radiation for head and neck squamous cell carcinoma.
  著者:: Justin P Williams, 等
  出版事項: (2014-01-01)
• Pre-Clinical Characterization of Dacomitinib (PF-00299804), an Irreversible Pan-ErbB Inhibitor, Combined with Ionizing Radiation for Head and Neck Squamous Cell Carcinoma
  著者:: Williams, Justin P., 等
  出版事項: (2014)
• Dacomitinib, a pan-inhibitor of ErbB receptors, suppresses growth and invasive capacity of chemoresistant ovarian carcinoma cells
  著者:: Momeny, Majid, 等
  出版事項: (2017)
• Comparative oncology: ErbB-1 and ErbB-2 homologues in canine cancer are susceptible to cetuximab and trastuzumab targeting
  著者:: Singer, Josef, 等
  出版事項: (2012)
• Dacomitinib (PF-00299804), a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor, demonstrates remarkable activity against HER2 amplified uterine serous endometrial cancer in vitro
  著者:: Zhu, Liancheng, 等
  出版事項: (2015)